Rate of progression determines the clinical outcome after neural transplantation in Parkinson's disease [1]

Brain

Volumn 129, Issue 7, 2006, Pages

  Linazasoro, G ^a  

^a Centro de Investigacion Parkinson   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DENERVATION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; HUMAN; LETTER; NERVE TRANSPLANTATION; OUTCOMES RESEARCH; PARKINSON DISEASE; PRIORITY JOURNAL; TISSUE GRAFT; TREATMENT OUTCOME; VENTRAL TEGMENTUM;

DISEASE PROGRESSION; FETAL TISSUE TRANSPLANTATION; HUMANS; MESENCEPHALON; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 33745713892     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl112     Document Type: Letter

References (12)

1. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
2. Brundin P, Pogarell O, Hagell P, Piccini P, Widner H, Schrag A, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 2000; 123: 1380-90.
3. Freed CR, Greene PE, Breeze RE, Wei-Yann T, DuMouchel W, Kao R, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710-9.
4. Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999; 56: 179-87.
5. Khan NL, Brooks DJ, Pavese N, Sweeney NG, Wood NW, Lees AJ, et al. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002; 125: 2248-56.
6. Linazasoro G. New ideas on the origin of L-dopa-induced dyskinesias: age, genes, neural plasticity. Trends Pharmacol Sci 2005; 26: 391-7.
7. Linazasoro G. Cell therapy for Parkinson's disease: Only young onset patients allowed? Cell Therapy 2006. In press.
8. Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002; 52: 628-34.
9. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-14.
10. Piccini P, Pavese N, Hagell P, Reimer J, Björklund A, Oertel WH, et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 2005; 128: 2977-86.
11. Thobois S, Ribeiro MJ, Lohmann E, Durr A, Pollak P, Rascol O, et al. Young-onset Parkinson disease with and without parkin gene mutations: a fluorodopa F 18 positron emission tomography study. Arch Neurol 2003; 60: 713-8.
12. Winkler C, Kirik D, Björklund A.. Cell transplantation in Parkinson's disease: how can we make it work. Trends Neurosci 2005; 28: 86-92.